Media - Our stories

Explore our recent stories to see what drives us

10 January 2023

Acquisition of Nebido®

Acquisition of Nebido®

“With our M&A strategy, we have increased profitability and diversified Grünenthal’s brand portfolio.”

Gabriel Beartschi

CEO, Grünenthal

Grünenthal agreed a deal to acquire Nebido® from Bayer AG in July 2022 and successfully completed the acquisition in November 2022. Nebido® is an established and well-known brand for treating male hypogonadism.

One in six men over 50 live with symptomatic androgen deficiency1. However, only one in ten men between the age of 30 to 79 with symptomatic androgen deficiency receive treatment2. The condition is caused by a reduced or absent secretion of testosterone from the testes.

Nebido® is a well-known brand in testosterone therapy. The product is directly administered by a physician every 10-14 weeks. Nebido® demonstrated a robust safety and efficacy profile backed with solid long-term data.

Nebido® is approved and successfully commercialised in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US.

1 Araujo, A. B., Esche, G. R., Kupelian, V., O’Donnell, A. B., Travison, T. G., Williams, R. E., ... & McKinlay, J. B. (2007). Prevalence of symptomatic androgen deficiency in men. The Journal of Clinical Endocrinology & Metabolism, 92(11), 4241-4247
2 Hall, S. A., Araujo, A. B., Esche, G. R., Williams, R. E., Clark, R. V., Travison, T. G., & McKinlay, J. B. (2008). Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Archives of internal medicine, 168(10), 1070-1076.


Grünenthal closes deal to acquire testosterone therapy Nebido® from Bayer for €495 million (PDF)

Grünenthal acquires testosterone treatment Nebido® from Bayer (PDF)

Further details on our company can be found in our annual report.



Get in touch

We are keen to hear new ideas and discover assets that are relevant to our business. If you are interested in partnering with us, get in touch.

Contact us


Share this story: